Trial Evaluating the Efficacy of the Combination of ROpivacaine With Reference XYlocaine in the Evaluation of Pain During the Installation of Percutaneous Radiological GASTrostomy

Cancer Clinical Trial

— GASTROXY  

Official title:

Trial Evaluating the Efficacy of the Combination of ROpivacaine With Reference XYlocaine in the Evaluation of Pain During the Installation of Percutaneous Radiological GASTrostomy

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04250805
• Other study ID #: 2019-1201
• Secondary ID: 2019-004835-22
• Status: Terminated
• Phase: Phase 2
• Start date: October 27, 2020
• Est. completion date: January 23, 2024

Study information

• Verified date: January 2024
• Source: Centre Hospitalier Universitaire de Saint Etienne
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Gastrostomy is an intra-gastric nutritional enteral device that could be put in place by percutaneous technique under radiological guidance: allowing local anesthesia. However, there is no clear recommendation about local analgesia during this exam. Operator can chose Lidocaine with a short period of action, or Ropivacaine with a longer period of action. The association of these two drugs could enhance the analgesia post procedure. The main objective of this study is to decrease maximal pain felt during a twenty four hour stay, after a gastrostomy under percutaneous technique with radiological guidance.

Description:

Gastrostomy is an intra-gastric nutritional enteral device, allowing the nutritional support for patients presenting oral feeding disorders. Gastrostomy could be put in place by different manners: - Chirurgical technique or endoscopy: with general anesthesia; - Percutaneous technique under radiological guidance: allowing local anesthesia. This last one is better tolerated by weak patients, and involves less complication. However, there is no clear recommendation about local analgesia during this exam. Operator can chose Lidocaine with a short period of action, or Ropivacaine with a longer period of action. The association of these two drugs could enhance the analgesia post procedure. Indeed, pain felt during the twenty four hours post procedure seems to be the most frequent adverse effect reported by patients. Pain could decrease significantly when Ropivacaine is added to the reference Xylocaine. Ropivacaine had already proved its efficacy in association with other antalgics. The main objective of this study is to decrease maximal pain felt during a twenty four hour stay, after a gastrostomy under percutaneous technique with radiological guidance.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 17
• Est. completion date: January 23, 2024
• Est. primary completion date: January 23, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria :

• Major patient;
• Having an indication for placement of PRG (percutaneous radiological gastrostomy);
• Patient hospitalized for a minimum of 24 hours post gastrostomy;

Non-inclusion criteria :

• Pregnant or lactating woman;
• Legal incapacity or limited legal capacity. Medical or psychological conditions which do not allow the subject to understand the study and sign the consent (art. L.1121-6, L.1121-7, L.1211-8, L.1211-9);
• Not knowing how to read and / or write French;
• Allergy and / or known hypersensitivity to lidocaine and / or ropivacaine or to other local anesthetics with amide bond or to one of the excipients;
• Recurrent porphyrias (genetic, hereditary diseases affecting the production of hemoglobin);
• Patient on beta blockers during the installation of PRG (Percutaneous Radiological Gastrostomy);
• Indication of gastrostomy button placement.

Related Conditions & MeSH terms

• Cancer
• Feeding and Eating Disorders
• Feeding Disorders

Intervention

Drug:
• Lidocaine
Patients will receive Lidocaine during percutaneous gastrostomy under radiological guidance.
• Ropivacaine
Patients will receive Ropivacaine during percutaneous gastrostomy under radiological guidance.

Locations

Country	Name	City	State
France	CHU de Saint-Etienne	Saint-Priest-en-Jarez
France	Institut de Cancérologie Lucien Neuwirth	Saint-Priest-en-Jarez

Sponsors (2)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Saint Etienne	Institut de Cancérologie de la Loire

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Level of Pain	Two points diminution for maximal pain felt during a twenty four hours after percutaneous gastrostomy under radiological guidance. It will be measured with a visual analogue scale starting at zero for no pain and ending at ten for maximal pain felt.	24 hours
Secondary	Level of Anxiety and Depression	Hospital Anxiety and Depression scores will be reported and analysed for each patient. This scale is an instrument for detecting anxiety and depressive disorders. It has 14 listed items from 0 to 3. Seven questions relate to anxiety (total A) and seven others relate to the depressive dimension (total D), allowing thus obtaining two scores (maximum score of each score = 21). To detect anxious and depressive symptoms, the following interpretation can be offered for each of the scores (A and D): 7 or less: absence of symptoms; 8 to 10: doubtful symptomatology; 11 and more: certain symptomatology.	10 days
Secondary	Level of quality of life	Brief Pain Inventory scores will be reported to evaluate the level of the patients' quality of life. For each question, score is comprised between 0 and 10, with 0 meaning no pain or no resounding on life activity, and 10 meaning the worst pain ever, and the worst resounding on life activity.	10 days
Secondary	Level of satisfaction	Patients' satisfaction about their analgesic care will be reported with a visual analogue scale starting at zero meaning no satisfaction, and ending at ten meaning the highest satisfaction possible.	10 days